Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.87, $0.01 better than the analyst estimate of $0.86. Revenue for the quarter came in at $241.2 million versus the consensus estimate of $241.11 million.

GUIDANCE:

Integra LifeSciences sees FY2016 EPS of $3.35-$3.50, versus the consensus of $3.43. Integra LifeSciences sees FY2016 revenue of $975-1000 million, versus the consensus of $974.2 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.